Situation

Our client had recently launched a novel autoinjector designed to enable subcutaneous administration of therapy for a rare tumor indication. The device represented a meaningful improvement over existing treatment options, which required frequent self-injection and were associated with low patient adherence and poor experience.

Despite a strong clinical rationale and a clear unmet need, the autoinjector experienced slower-than-expected uptake post-launch, prompting the need to identify adoption barriers and unlock the product’s commercial potential.

Approach

HealthQuest was engaged to assess the underlying drivers of limited uptake and develop a targeted strategy to accelerate adoption. A structured root-cause assessment was conducted, combining stakeholder interviews, evaluation of market access dynamics, and analysis of existing provider engagement approaches. This assessment identified key disconnects between the product’s clinical value and physician perception, as well as gaps in how the value proposition was communicated.

Building on these insights, HealthQuest refined the clinical and economic value proposition by quantifying the burden of existing treatment approaches and identifying patient segments most likely to benefit from the autoinjector. To support execution, HealthQuest created a comprehensive evidence-based toolkit articulating the clinical benefits and economic impact of the device, including estimated reductions in acute care utilization.

Impact

HealthQuest equipped the client’s commercial team with a clear, differentiated value proposition and targeted engagement strategy to support a product relaunch.

The engagement provided a refined view of the addressable market, prioritized high-need patient segments, and enabled more effective physician engagement through data-driven materials demonstrating both clinical value and economic return.